Healthcare
DarioHealth Corp.(DRIO)
Live Price
Offline$6.34
-8.51% today
1Y Change
-56.47%
Window
Jun 25, 2025 โ Jun 24, 2026
- Market Cap
- $60.00M
- Revenue Growth
- -17.3%
- EPS Growth
- +267.6%
- Dividend Yield
- 0.0%
Coverage: 251 bars ยท Jun 25, 2025 โ Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
DarioHealth Corp. (DRIO) is a Healthcare stock with a market cap of $60.00M and listed on NASDAQ. The stock last traded around $6.34 and down 56.5% across the available one-year price window (Jun 25, 2025 โ Jun 24, 2026). Baseline metrics include revenue growth of -17.3%, EPS growth of +267.6%, a dividend yield of 0.0%. What stands out right now is revenue -17.3%, EPS +267.6%, free cash flow +32.6% with operating margin -163.9% and ROIC -36.2%. Valuation is more restrained than many high-expectation growth names at P/E 6.4 and price/sales 2.6. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines DRIO price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-17.3% vs +7.6% peer median
Operating Margin
Below sector median
-163.9% vs +19.4% peer median
P/E
Below sector median
6.4 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 13, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -17.3% and EPS is at +267.6%, with operating margin around -163.9%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +13.5% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 13, 2026 | โ | +3.5% | -1.2% | -11.1% |
2026 Mar 19, 2026 | +67.2% | -3.0% | +2.5% | -11.9% |
2025 Nov 13, 2025 | +29.7% | +18.2% | +39.3% | +19.9% |
Benchmark Edge
DRIO vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
DRIO
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
DRIO Max Drawdown
-65.48%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for DRIO and SPY.
Company Overview
DarioHealth Corp.
NASDAQ Capital Market
DarioHealth Corp. operates as a digital therapeutics company in the United States, Canada, the European Union, Australia, and New Zealand. The company offers Dario's metabolic solutions to address metabolic health needs, such as diabetes, hypertension, and weight management; Dario Musculoskeletal, which helps to prevent and treat the most common MSK conditions; Dario's behavioral health solution that optimizes access to evidence-based care; chronic condition management solutions; DarioEngage, a proprietary care management platform; and device-specific disposables test strip cartridges, lancets, and blood glucose monitoring systems. It also provides smart glucose meters; bluetooth connected blood pressure cuff; digital scales; biofeedback sensor devices; and diabetes management programs, including lifestyle changes, healthy eating, advanced tracking, and live coaching. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.
- Leadership
- Erez Raphael
- IPO Date
- Mar 14, 2016
- Employees
- 196
- Street Address
- 18 West 18th Street
- Mailing
- New York City, NY, 10011
- Region
- New York City, NY, US
- Reporting Currency
- USD
- Investor Line
- 833 914 3796
- Last Updated
- Apr 28, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 6.4
- EV/EBITDA
- โ
- Price/Sales
- 2.6
- Price/Book
- 5.8
Growth
- Revenue
- -17.3%
- EPS
- +267.6%
- Free Cash Flow
- +32.6%
Profitability
- Gross Margin
- 56.6%
- Operating Margin
- -163.9%
- Net Margin
- 276.1%
- ROE
- 88.0%
- ROIC
- -36.2%
Balance Sheet
- Debt/Equity
- 0.47
- Current Ratio
- 3.73
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.